Clinical Psychopharmacology and Neuroscience

Korean College of Neuropsychopharmacology (대한정신약물학회)
권호 표지
DOI QR코드

DOI QR Code

Predictors of Cognitive Improvement during 12 Weeks of Antidepressant Treatment in Patients with Major Depressive Disorder

  • Lee, Jeong-Ok (Department of Psychiatry, Naju National Hospital) ;
  • Kim, Ju-Wan (Department of Psychiatry, Chonnam National University Medical School) ;
  • Kang, Hee-Ju (Department of Psychiatry, Chonnam National University Medical School) ;
  • Hong, Jin-Pyo (Department of Psychiatry, Sungkyunkwan University School of Medicine) ;
  • Kim, Jae-Min (Department of Psychiatry, Chonnam National University Medical School)
  • Received : 2018.02.01
  • Accepted : 2018.05.28
  • Published : 2018.11.30
⟨ Previous Next ⟩

Abstract

Objective: Cognitive disturbance is one of the major symptoms of depression and may be improved by treatment with antidepressants. This study aimed to investigate the predictors of cognitive improvement in patients with major depressive disorder (MDD) who were taking antidepressants. Methods: This study included 86 patients with MDD who completed 12 weeks of antidepressant monotherapy. Cognitive symptoms were assessed using the Perceived Deficits Questionnaire-Korean version (PDQ-K), which addresses four domains of cognitive functioning (attention/concentration, retrospective memory, prospective memory, and organization/planning) and was administered at study entry and at the 12-week end point. A variety of demographic, clinical, and treatment-related variables were evaluated as predictors of changes in total and domain scores. Results: All PDQ-K domains showed significant improvement after 12 weeks of antidepressant treatment. More severe initial depressive symptoms, fewer sick-leave days at study entry, and reduced use of concomitant anxiolytics/hypnotics during treatment were significantly associated with greater cognitive improvement. Conclusion: Cognitive symptoms are more responsive to antidepressant treatment in patients with severe MDD. Reduced use of anxiolytics and hypnotics could improve the cognitive functioning of patients with MDD taking antidepressants.

Keywords

Acknowledgement

Supported by : Korea Health Industry Development Institute (KHIDI)

References

  1. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). Jama 2003;289:3095-3105. https://doi.org/10.1001/jama.289.23.3095
  2. Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression, chronic diseases, and decrements in health: results from the world health surveys. Lancet 2007;370:851-858. https://doi.org/10.1016/S0140-6736(07)61415-9
  3. Stewart WF, Ricci JA, Chee E, Hahn SR, Morganstein D. Cost of lost productive work time among US workers with depression. JAMA 2003;289:3135-3144. https://doi.org/10.1001/jama.289.23.3135
  4. American Psychiatry Association; American Psychiatric Association. DSM-5 Task Force. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington, DC:American Psychiatric Association;2013.
  5. Judd LL, Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 1998;50:97-108. https://doi.org/10.1016/S0165-0327(98)00138-4
  6. Jaeger J, Berns S, Uzelac S, Davis-Conway S. Neurocognitive deficits and disability in major depressive disorder. Psychiatry Res 2006;145:39-48. https://doi.org/10.1016/j.psychres.2005.11.011
  7. Woo YS, Rosenblat JD, Kakar R, Bahk WM, McIntyre RS. Cognitive deficits as a mediator of poor occupational function in remitted major depressive disorder patients. Clin Psychopharmacol Neurosci 2016;14:1-16. https://doi.org/10.9758/cpn.2016.14.1.1
  8. Kim HG, Kong EJ, Cheon EJ, Kim HW, Koo BH. Association between cerebral amyloid deposition and clinical factors including cognitive function in geriatric depression: pilot study using amyloid positron emission tomography. Clin Psychopharmacol Neurosci 2016;14:378-382. https://doi.org/10.9758/cpn.2016.14.4.378
  9. Danner M, Hummel JM, Volz F, van Manen JG, Wiegard B, Dintsios CM, et al. Integrating patients' views into health technology assessment: analytic hierarchy process (AHP) as a method to elicit patient preferences. Int J Technol Assess Health Care 2011;27:369-375. https://doi.org/10.1017/S0266462311000523
  10. Soczynska JK, Ravindran LN, Styra R, McIntyre RS, Cyriac A, Manierka MS, et al. The effect of bupropion XL and escitalopram on memory and functional outcomes in adults with major depressive disorder: results from a randomized controlled trial. Psychiatry Res 2014;220:245-250. https://doi.org/10.1016/j.psychres.2014.06.053
  11. Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RS. A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology 2015;40:2025-2037. https://doi.org/10.1038/npp.2015.52
  12. Rosenblat JD, Kakar R, McIntyre RS. The cognitive effects of antidepressants in major depressive disorder: a systematic review and meta-analysis of randomized clinical trials. Int J Neuropsychopharmacol 2015;19:pyv082.
  13. Keefe RS, McClintock SM, Roth RM, Doraiswamy PM, Tiger S, Madhoo M. Cognitive effects of pharmacotherapy for major depressive disorder: a systematic review. J Clin Psychiatry 2014;75:864-876. https://doi.org/10.4088/JCP.13r08609
  14. Elgamal S, Denburg S, Marriott M, MacQueen G. Clinical factors that predict cognitive function in patients with major depression. Can J Psychiatry 2010;55:653-661. https://doi.org/10.1177/070674371005501004
  15. Gu CZ, He HL, Duan HF, Su ZH, Chen H, Gan JL. Predictors of neurocognitive impairment at 2years after a first-episode major depressive disorder. Compr Psychiatry 2016;68:24-33. https://doi.org/10.1016/j.comppsych.2016.03.009
  16. Evans VC, Iverson GL, Yatham LN, Lam RW. The relationship between neurocognitive and psychosocial functioning in major depressive disorder: a systematic review. J Clin Psychiatry 2014;75:1359-1370. https://doi.org/10.4088/JCP.13r08939
  17. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59 Suppl 20:22-33;quiz 34-57.
  18. Kim JM, Hong JP, Kim SD, Kang HJ, Lee YS. Development of a Korean version of the Perceived Deficits Questionnaire-Depression for Patients with Major Depressive Disorder. Clin Psychopharmacol Neurosci 2016;14:26-32. https://doi.org/10.9758/cpn.2016.14.1.26
  19. Takasaki H, Chien CW, Johnston V, Treleaven J, Jull G. Validity and reliability of the perceived deficit questionnaire to assess cognitive symptoms in people with chronic whip-lash-associated disorders. Arch Phys Med Rehabil 2012;93:1774-1781. https://doi.org/10.1016/j.apmr.2012.05.013
  20. McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol 2014;17:1557-1567. https://doi.org/10.1017/S1461145714000546
  21. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389. https://doi.org/10.1192/bjp.134.4.382
  22. Leon AC, Olfson M, Portera L, Farber L, Sheehan DV. Assessing psychiatric impairment in primary care with the Sheehan disability scale. Int J Psychiatry Med 1997;27:93-105. https://doi.org/10.2190/T8EM-C8YH-373N-1UWD
  23. EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208. https://doi.org/10.1016/0168-8510(90)90421-9
  24. Bose A, Tsai J, Li D. Early non-response in patients with severe depression: escitalopram up-titration versus switch to duloxetine. Clin Drug Investig 2012;32:373-385. https://doi.org/10.2165/11631890-000000000-00000
  25. McDermott LM, Ebmeier KP. A meta-analysis of depression severity and cognitive function. J Affect Disord 2009;119:1-8. https://doi.org/10.1016/j.jad.2009.04.022
  26. de Vries G, Koeter MW, Nabitz U, Hees HL, Schene AH. Return to work after sick leave due to depression; a conceptual analysis based on perspectives of patients, supervisors and occupational physicians. J Affect Disord 2012;136: 1017-1026. https://doi.org/10.1016/j.jad.2011.06.035
  27. Blank L, Peters J, Pickvance S, Wilford J, Macdonald E. A systematic review of the factors which predict return to work for people suffering episodes of poor mental health. J Occup Rehabil 2008;18:27-34. https://doi.org/10.1007/s10926-008-9121-8
  28. Cai H, Li G, Hua S, Liu Y, Chen L. Effect of exercise on cognitive function in chronic disease patients: a meta-analysis and systematic review of randomized controlled trials. Clin Interv Aging 2017;12:773-783. https://doi.org/10.2147/CIA.S135700
  29. Kramer AF, Erickson KI, Colcombe SJ. Exercise, cognition, and the aging brain. J Appl Physiol (1985) 2006;101:1237- 1242. https://doi.org/10.1152/japplphysiol.00500.2006
  30. Barker MJ, Greenwood KM, Jackson M, Crowe SF. Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs 2004;18:37-48. https://doi.org/10.2165/00023210-200418010-00004
  31. Verster JC, Volkerts ER, Verbaten MN. Effects of alprazolam on driving ability, memory functioning and psychomotor performance: a randomized, placebo-controlled study. Neuropsychopharmacology 2002;27:260-269. https://doi.org/10.1016/S0893-133X(02)00310-X
  32. Yang SJ, Kim SY, Stewart R, Kim JM, Shin IS, Jung SW, et al. Gender differences in 12-week antidepressant treatment outcomes for a naturalistic secondary care cohort: the CRESCEND study. Psychiatry Res 2011;189:82-90. https://doi.org/10.1016/j.psychres.2010.12.027
  33. McIntyre RS. Using measurement strategies to identify and monitor residual symptoms. J Clin Psychiatry 2013;74 Suppl 2:14-8. https://doi.org/10.4088/JCP.12084su1c.03
  34. Raskin J, Wiltse CG, Siegal A, Sheikh J, Xu J, Dinkel JJ, et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 2007;164:900-909. https://doi.org/10.1176/ajp.2007.164.6.900

Cited by

  1. Posttraumatic Embitterment Disorder in Patients with Chronic Kidney Disease vol.17, pp.2, 2018, https://doi.org/10.9758/cpn.2019.17.2.183
  2. Paradoxical Motor and Cognitive Function Recovery in Response to Zolpidem in a Patient with Hypoxic-ischemic Brain Injury: A Case Report vol.17, pp.3, 2018, https://doi.org/10.9758/cpn.2019.17.3.453
  3. Baseline predictors of cognitive change in the treatment of major depressive episode: systematic review vol.6, pp.6, 2018, https://doi.org/10.1192/bjo.2020.114
  4. Predictors of Cognitive Improvement Following Treatment for Late-Life Depression vol.34, pp.2, 2018, https://doi.org/10.1177/0891988720915515